Dirlotapide - CAS 481658-94-0
Catalog number:
481658-94-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C40H33F3N4O3
Molecular Weight:
674.71
COA:
Inquire
Targets:
Others
Description:
Dirlotapide is a drug used to treat obesity in dogs works as a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥95%
Appearance:
Solid powder
Synonyms:
Slentrol; 5-((4'-Trifluoromethyl-biphenyl-2-carbonyl)amino)-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
MTTP Inhibitor
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
InChIKey:
TUOSYWCFRFNJBS-BHVANESWSA-N
InChI:
1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1
Canonical SMILES:
CN(Cc1ccccc1)C(=O)[C@@H](NC(=O)c2cc3cc(NC(=O)c4ccccc4c5ccc(cc5)C(F)(F)F)ccc3n2C)c6ccccc6
1.An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe.
Gossellin J1, McKelvie J, Sherington J, Wren JA, Eagleson JS, Rowan TG, Sunderland SJ. J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:73-80.
The clinical efficacy for weight loss and safety of dirlotapide in dogs were evaluated in two multi-centre studies with parallel designs. Overweight, adult dogs (n = 245) of various breeds were randomized to treatment with dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg/day commencing on day 0 and doubled after 14 days. Every 28 days, dogs were examined, weighed, body condition scores (BCS) were recorded, and dose was adjusted to meet weight loss targets. Each study comprised three consecutive phases: weight-loss (up to day 196); weight-stabilization (84 days); and post-treatment (28 days). pre-treatment feeding and exercise regimens were continued during treatment. Dirlotapide-treated dogs showed mean weight loss of 15.9% (study A) and 14.0% (study B) by the end of weight loss phase (up to day 196). Percentage weekly weight losses for dirlotapide were significantly greater than for placebo (P < or = 0.
2.Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs.
Kirk CA1, Boucher JF, Sunderland SJ, Wren JA. J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:66-72.
The objectives of this study were to evaluate the effects of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on apparent nutrient digestibility of an expanded dry dog food, on defecation frequency and fecal consistency. Eighteen beagles were randomized to either placebo (n = 6) or dirlotapide (n = 12). Testing was divided into a 21-day adaptation phase (days -21 to -1) and a 35-day treatment (digestibility testing) phase (days 0-35). During the treatment phase, dogs were administered oral dirlotapide (0.3 mg/kg) or placebo (0.06 mL/kg) once daily. For digestibility testing, feces were collected over two periods for 7 days each starting on days -9 and 28. All dogs were fed a commercial adult dog food throughout the study. Food intake was adjusted to maintain body weight during adaptation, followed by pair-feeding placebo dogs the amount of food ingested by the dirlotapide dogs during the treatment period. Dogs in both groups had reduced food intake and lost similar amounts of body weight during treatment.
3.Evaluation of dirlotapide for sustained weight loss in overweight Labrador retrievers.
Gossellin J1, Peachey S, Sherington J, Rowan TG, Sunderland SJ. J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:55-65.
The effects of dirlotapide on body weight (BW) reduction were investigated in overweight Labradors in two parallel-design studies. Study A involved 42 dogs randomized to 0.0, 0.025, 0.05, 0.1, 0.2 or 0.4 mg dirlotapide/kg/day orally for 4 weeks. Study B involved 72 dogs randomized to nine treatments: placebo (24 weeks); dirlotapide (24 weeks) followed by placebo (28 weeks); or dirlotapide (52 weeks); on diets containing 5%, 10% or 15% fat. Dirlotapide dose (initially 0.1 mg/kg) was adjusted monthly during 24-week weight-loss and subsequent 28-week weight-stabilization phases. Food was offered above maintenance energy requirements (MERx 1.1-1.2) based on initial BW. Body composition (body fat, lean tissue and bone mineral content) was monitored using dual-energy X-ray absorptiometry. After treatment, dogs that had received dirlotapide for 52 weeks were fed 90% of quantity consumed at week 52. In study A, BW and food intake decreased asymptotically with dose: mean weekly weight loss exceeded 1% at 0.
4.Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide.
Robinson RP1, Bartlett JA, Bertinato P, Bessire AJ, Cosgrove J, Foley PM, Manion TB, Minich ML, Ramos B, Reese MR, Schmahai TJ, Swick AG, Tess DA, Vaz A, Wolford A. Bioorg Med Chem Lett. 2011 Jul 15;21(14):4150-4. doi: 10.1016/j.bmcl.2011.05.099. Epub 2011 Jun 2.
Analogues related to dirlotapide (1), a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) were prepared with the goal of further reducing the potential for unwanted liver MTP inhibition and associated side-effects. Compounds were designed to decrease active metabolite load: reducing MTP activity of likely human metabolites and increasing metabolite clearance to reduce exposure. Introduction of 4'-alkyl and 4'-alkoxy substituents afforded compounds exhibiting improved therapeutic index in rats with respect to liver triglyceride accumulation and enzyme elevation. Likely human metabolites of select compounds were prepared and characterized for their potential to inhibit MTP in vivo. Based on preclinical efficacy and safety data and its potential for producing short-lived, weakly active metabolites, compound 13 (PF-02575799) advanced into phase 1 clinical studies.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 126-17-0 Solasodine

Solasodine
(CAS: 126-17-0)

Solasodine is a neuroprotective antioxidant glycoalkaloid of Solanum species. Solasodine increases superoxide dismutase (SOD), catalase (CAT),and glutathione (G...

CAS 6055-19-2 Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate
(CAS: 6055-19-2)

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA. It is used to treat cancers and aut...

CAS 4618-18-2 Lactulose

Lactulose
(CAS: 4618-18-2)

Lactulose, a disaccharide composed of galactose and fructose, is a stimulator of health-promoting bacterium growth in the gastrointestinal tract, used to treat ...

CAS 73-31-4 Melatonin

Melatonin
(CAS: 73-31-4)

Melatonin is a hormone produced in the brain by the pineal gland from the amino acid tryptophan. It can be used as a antioxidant therapy. Melatonin is involved ...

CAS 152751-57-0 Sevelamer HCl

Sevelamer HCl
(CAS: 152751-57-0)

Sevelamer HCl is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption.

CAS 80321-63-7 Gynostemma Extract

Gynostemma Extract
(CAS: 80321-63-7)

Gynostemma Extract is a saponins extract derived from the Gynostemma pentaphyllum.

CAS 110314-48-2 Adolezesin

Adolezesin
(CAS: 110314-48-2)

Adozelesin is an experimental antitumor drug of the duocarmycin class. It is the first of a class of DNA-sequence-selective alkylating agents. It binds to and a...

CAS 115810-12-3 Tubeimoside II

Tubeimoside II
(CAS: 115810-12-3)

Tubeimoside II is a natural analogue of oleanane type of triterpenoid saponin, showing anti-inflammatory, antitumor, and antitumor-promoting effects.

CAS 51037-30-0 Acipimox

Acipimox
(CAS: 51037-30-0)

Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, ...

CAS 485-72-3 Formononetin

Formononetin
(CAS: 485-72-3)

Formononetin is a phytoestrogen from the root of Astragalus membranaceus and an O-methylated isoflavone.

BI-44847
(CAS: 421592-30-5)

BI-44847 is a synthetic bio-active chemical had been in phase II clinical trials for the treatment of type 2 diabetes.

CAS 84687-42-3 Astragaloside III

Astragaloside III
(CAS: 84687-42-3)

Astragaloside III is a saponin found in the root of Astragalus membranaceus (Fisch.) Bunge, which is known as huáng qí in Traditional Chinese Medicine. It has c...

Cp-76593
(CAS: 115898-30-1)

This active molecular is a bio-active chemical and detailed information has not been published yet.

CAS 886992-99-0 Ac-Gly-BoroPro

Ac-Gly-BoroPro
(CAS: 886992-99-0)

A selective FAP inhibitor (Ki= 23 nM)

CAS 34097-16-0 Clocortolone Pivalate

Clocortolone Pivalate
(CAS: 34097-16-0)

Clocortolone Pivalate is a Corticosteroid Hormone Receptor Agonist. It is used for the treatment of dermatitis and is considered a medium-strength corticosteroi...

CAS 58821-95-7 Tinyatoxin

Tinyatoxin
(CAS: 58821-95-7)

Tinyatoxin is a neurotoxin, acting via vanilloid receptors of sensory nerves.

SBC-115076
(CAS: 489415-96-5)

SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist. .

CAS 28860-95-9 Carbidopa

Carbidopa
(CAS: 28860-95-9)

Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 μM.

CAS 36062-07-4 Octahydrocurcumin

Octahydrocurcumin
(CAS: 36062-07-4)

OKT3-induced PBMC proliferation was inhibited by octahydrocurcumin with IC50 of 82 uM. The investigated substances with the strongest effect on radical scavengi...

CAS 1579991-63-1 Chitinase-IN-2

Chitinase-IN-2
(CAS: 1579991-63-1)

Chitinase-IN-2 is a insect chitinase and N- acetyl hexosaminidase inhibitor and pesticide; 50 uM/20uM compound concentration&#39;s inhibitory percentage are 98%...

Quick Inquiry

Verification code

Featured Items